Generate Biomedicines Reports Q2 Cash of $457M, Advances Phase 3 Asthma Trials
GENB sits 30% above its 52-week low of $11.
Summary
Generate Biomedicines reported Q2 2026 results with $457.4 million in cash, a net loss of $67.3 million, and progress across its pipeline. The cash position, following its recent IPO, funds operations into 2028. Key updates include global enrollment underway for Phase 3 SOLAIRIA studies of GB-0895 in severe asthma, upcoming COPD data at ERS on Sept. 8, and full enrollment in the first cohort of the Phase 1 GB-4362 study. Novartis advanced a Generate-designed biologic into preclinical development, marking the first AI-engineered biologic to reach that stage. The financials and pipeline milestones provide a baseline for the newly public company, with multiple data readouts expected in the coming months.
At the time of this announcement, GENB was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $11.00 to $18.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.